According to filings with the U.S. Securities and Exchange Commission, Imaginostics is raising up to $7,595,768.00 in new funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.

About Imaginostics
Imaginostics is bringing to market breakthrough vascular imaging. Rooted in MRI physics, our innovative imaging technology provides 10X better images compared to MRI w/ Gadolinium (100X better than MRI w/o contrast) and, first the first time, quantitative measurements of the vascular structure, function, and leakage of small blood vessels. We are creating the next generation of precision medicine diagnostic and prognostic tools to serve clinicians and drug developers to transform personalized healthcare, accelerate drug development, and fight aging.

To learn more about Imaginostics, visit https://imaginostics.com/
Imaginostics Linkedin Page: https://www.linkedin.com/company/imaginostics/

Contact:
Valerie Gharagouzloo, Chief Executive Officer
833-674-7226
https://www.linkedin.com/in/vghara/

SOURCE: http://www.intelligence360.io
Copyright (c) 2026 SI360 Inc. All rights reserved.